IP Library Granted Patent US 10,610,485
Granted Patent B2
US 10,610,485 · App. 16/266,305 · Granted Apr 7, 2020

Methotrexate composition

Inventors: Carl Tierney (Leeds, GB); Stacey Powell (Leeds, GB); Peter Braybrooke (Leeds, GB); Geraint Jones (Leeds, GB)
Assignee: Rosemont Pharmaceuticals Ltd
A61K9/08A61K9/0053A61K9/0095A61K31/519A61K47/02A61K47/12A61K47/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,610,485
App. No.
16/266,305
Granted
Apr 7, 2020
Kind
B2
Abstract

A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Claims (13)

1. A Methotrexate composition for oral administration, said composition consisting of a pharmaceutically acceptable salt of Methotrexate, a citrate buffer system, a preserving agent, a sweetening agent, and purified water, wherein a pharmaceutically acceptable dosage of the Methotrexate salt used in the composition is in the range of 0.05 mg/1 ml to 20 mg/1 ml, and wherein the pH of the composition is 6 to 7.

2. The Methotrexate composition according to claim 1 wherein the pharmaceutically acceptable salt of Methotrexate used is Methotrexate disodium.

3. The Methotrexate composition according to claim 1 wherein the pH of the composition is in the range of pH 6.1-6.5.

4. The Methotrexate composition according to claim 1 wherein the pH of the composition is in the range of pH 6.25+/−0.15.

5. The Methotrexate composition according to claim 1 wherein the citrate buffer system comprises Citric Acid and Sodium Citrate.

6. The Methotrexate composition according to claim 1 wherein the citrate buffer system has a strength between 2 to 200 millimolar.

7. The Methotrexate composition according to claim 1 wherein the preserving agent comprises any or any combination of Sodium Methyl Hydroxybenzoate, Sodium Ethyl Hydroxybenzoate, Sodium Propyl Hydroxybenzoate, Sodium Benzoate or Potassium Sorbate.

8. The Methotrexate composition according to claim 1 wherein the preserving agent comprises Sodium Methyl Hydroxybenzoate or Sodium Propyl Hydroxybenzoate.

9. The Methotrexate composition according to claim 1 wherein the sweetening agent comprises Sucralose, Acesulfame K, or any other water soluble sweetener.

10. The Methotrexate composition according to claim 1 wherein the sweetening agent comprises Sucralose.

11. The Methotrexate composition according to claim 1 wherein the pharmaceutically acceptable dosage of the Methotrexate salt used in the composition is 10 mg/5 ml.

12. The Methotrexate composition according to claim 1 wherein a pharmaceutically acceptable dosage of the Methotrexate salt used is equivalent to 2.5 mg/1 ml methotrexate base.

13. The Methotrexate composition according to claim 1 wherein the citrate buffer system has a strength between 2 to 20 millimolar.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2019
From: TIERNEY, CARL; POWELL, STACEY; BRAYBROOKE, PETER; JONES, GERAINT
To: ROSEMONT PHARMACEUTICALS LTD
Reel/Frame 048239/0543 →
Priority Claims (1)
GB 1200192.1 · Jan 6, 2012 · national
Continuity (4)
Continuation 15821242 · Nov 22, 2017
Continuation 15019244 · Feb 9, 2016
Continuation 13733031 · Jan 2, 2013
Related Publication 20190167582A1 · Jun 6, 2019
Cited By (1)
US 12,396,947